Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced positive topline results from the US Phase 3 ConfIdeS trial of imlifidase, evaluating 12-month kidney function ...
Using the PREVENT-CVD equation to guide management of high blood pressure could improve outcomes by identifying individuals ...
Researchers report favorable safety and efficacy for a combination device after implantation and at 6 months follow-up among ...
Chronic liver disease (CLD) is prevalent worldwide, but clinicians often struggle to identify the precise aetiology. Renal involvement in CLD is also puzzling, with varied pathologies and risk factors ...
Electric Drive Evolution: Sixth Generation eDrive Technology, Efficiency and Range Fully Enhanced ...
Once-daily oral GLP-1 drug orforglipron leads to significant, dose-dependent weight loss and metabolic benefits without diabetes.
Detailed price information for Maze Therapeutics Inc (MAZE-Q) from The Globe and Mail including charting and trades.
MarketNewsUpdates News Commentary NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy ...
Results from a large trial suggest baxdrostat could provide a new option for people whose blood pressure remains high despite standard treatment.
HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for metabolic diseases, announced that ...
Vitamin D significantly affects IBD by influencing severity, inflammation, and patient outcomes. Optimizing vitamin D levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback